INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of “Hold” by Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have been given an average rating of “Hold” by the six research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.00.

A number of equities analysts have recently weighed in on the company. Lucid Cap Mkts raised INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Wall Street Zen lowered INmune Bio from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INmune Bio in a research report on Thursday.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of INmune Bio during the fourth quarter worth approximately $32,000. XTX Topco Ltd raised its position in shares of INmune Bio by 41.3% during the fourth quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock worth $107,000 after purchasing an additional 20,121 shares during the period. Quadrature Capital Ltd acquired a new position in shares of INmune Bio during the fourth quarter worth approximately $26,000. Jain Global LLC acquired a new position in shares of INmune Bio during the fourth quarter worth approximately $66,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of INmune Bio by 20.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock worth $78,000 after purchasing an additional 8,427 shares during the period. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Stock Performance

Shares of INMB opened at $1.28 on Tuesday. INmune Bio has a 52-week low of $1.09 and a 52-week high of $11.64. The business’s 50 day moving average price is $1.37 and its two-hundred day moving average price is $1.48. The firm has a market cap of $34.02 million, a PE ratio of -0.77 and a beta of 1.03.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.